The 36-month beta value for CLRB is also noteworthy at 0.96. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CLRB is 39.40M, and at present, short sellers hold a 4.66% of that float. The average trading volume of CLRB on November 15, 2024 was 239.05K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CLRB) stock’s latest price update
The stock of Cellectar Biosciences Inc (NASDAQ: CLRB) has decreased by -6.47 when compared to last closing price of 2.01.Despite this, the company has seen a loss of -11.32% in its stock price over the last five trading days. globenewswire.com reported 2024-11-14 that NorthStar to provide Cellectar with non-carrier-added Ac-225 for its expanded portfolio of clinical programs
CLRB’s Market Performance
Cellectar Biosciences Inc (CLRB) has experienced a -11.32% fall in stock performance for the past week, with a -8.74% drop in the past month, and a -8.29% drop in the past quarter. The volatility ratio for the week is 4.99%, and the volatility levels for the past 30 days are at 4.32% for CLRB. The simple moving average for the past 20 days is -8.78% for CLRB’s stock, with a -32.44% simple moving average for the past 200 days.
Analysts’ Opinion of CLRB
ROTH Capital, on the other hand, stated in their research note that they expect to see CLRB reach a price target of $10. The rating they have provided for CLRB stocks is “Buy” according to the report published on January 21st, 2020.
CLRB Trading at -9.40% from the 50-Day Moving Average
After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.75% of loss for the given period.
Volatility was left at 4.32%, however, over the last 30 days, the volatility rate increased by 4.99%, as shares sank -8.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.91% lower at present.
During the last 5 trading sessions, CLRB fell by -9.65%, which changed the moving average for the period of 200-days by -51.26% in comparison to the 20-day moving average, which settled at $2.06. In addition, Cellectar Biosciences Inc saw -32.13% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLRB
Current profitability levels for the company are sitting at:
- -144.28 for the present operating margin
- 0.15 for the gross margin
The net margin for Cellectar Biosciences Inc stands at -132.22. The total capital return value is set at -3.35. Equity return is now at value -739.69, with -274.00 for asset returns.
Based on Cellectar Biosciences Inc (CLRB), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -583.94. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -384.3.
Currently, EBITDA for the company is -38.77 million with net debt to EBITDA at 0.53. When we switch over and look at the enterprise to sales, we see a ratio of 159.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
In summary, Cellectar Biosciences Inc (CLRB) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
